Last Price$19.1(7.5%)
Market Cap$14.6B
LTM EBITDA
($212.6M)
YoY Growth
-64.4%
3Y CAGR
+29.1%
5Y CAGR
+42.8%
Stock quality & Intrinsic value
6/10
97.4% overvalued
Summit Therapeutics Inc. EBITDA
Annual
Quarterly
LTM
Crunching data... Almost there!
| Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | ($5,381.2K) | ($11.4M) | ($37.2M) | ($29.0M) | ($8,539.0K) | ($13.3M) | ($7,059.8K) | ($8,709.9K) | ($17.3M) | ($20.0M) | ($30.9M) | ($41.5M) | ($41.9M) | $15.5M | ($21.4M) | ($37.1M) | ($62.7M) | ($52.6M) | $1,001.0K | $313.0K |
Overvalued or undervalued?
Check the intrinsic value for SMMT
and see if it's the right time to invest.
Summit Therapeutics Inc. (SMMT) EBITDA comparison analysis
General
LTM EBITDA
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Summit Therapeutics Inc.SMMT
($212.6M)
(64.4%)
29.1%
50.0%
Median Peer Set
$375.0M
(13.0%)
(8.9%)
(4.9%)
Novo Nordisk A/SNVO
$21.5B
26.9%
30.1%
20.6%
Regeneron Pharmaceuticals, Inc.REGN
$4,705.5M
(0.7%)
(21.8%)
13.6%
Royalty Pharma plcRPRX
$1,834.8M
2.1%
10.0%
(7.1%)
United Therapeutics CorporationUTHR
$1,607.4M
22.7%
32.7%
N/A
Vertex Pharmaceuticals IncorporatedVRTX
$486.3M
(89.4%)
(45.0%)
(20.8%)
Incyte CorporationINCY
$263.8M
(67.2%)
(26.5%)
(13.5%)
argenx SEARGX
($47.4M)
(81.7%)
N/A
(19.0%)
Alnylam Pharmaceuticals, Inc.ALNY
($193.0M)
(25.3%)
(33.7%)
(26.3%)
BioNTech SEBNTX
($402.2M)
N/A
N/A
33.9%
BeiGene, Ltd.BGNE
($730.3M)
(39.9%)
(17.7%)
(2.7%)
SMMT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1.7 338.9% | 3.8 119.8% | 12.1 219.9% | 0.5 (96.0%) | 0.5 (1.1%) | 1.9 290.6% | 4.4 138.3% | 4.6 2.5% | 3.6 (21.8%) | 3.7 4.3% | 0.0 (100.0%) | 3.9 0.0% | 46.8 1,114.8% | 74.9 59.9% | 0.8 (98.9%) | 0.9 6.6% | 1.8 110.3% | 0.7 (61.1%) | 0.0 (100.0%) | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.8 | 1.1 | 5.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 2.5 | 2.1 | 15.0 |
% margin | 1.0 56.1% | 2.7 70.6% | 7.0 58.3% | 0.5 97.8% | 0.5 100.0% | 1.9 100.0% | 2.8 63.7% | 4.6 100.0% | 3.6 100.0% | 3.7 100.0% | 0.0 0.0% | 3.9 100.0% | 46.7 99.7% | 74.8 100.0% | 0.6 75.4% | 0.9 100.0% | 1.8 100.0% | (1.8) (257.0%) | (2.1) 0.0% | (15.0) 0.0% |
| Operating Expenses | 6.8 | 18.6 | 53.9 | 27.9 | 15.0 | 8.6 | 11.9 | 13.5 | 20.9 | 31.6 | 44.8 | 45.4 | 70.4 | 63.3 | 53.6 | 53.2 | 88.0 | 64.3 | 87.7 | 211.3 |
| Research & Development Expenses (R&D) | 3.3 | 10.8 | 30.7 | 13.3 | 5.8 | 5.7 | 7.7 | 9.1 | 17.0 | 25.6 | 36.4 | 31.7 | 53.4 | 68.2 | 41.7 | 53.3 | 85.4 | 52.0 | 59.5 | 150.8 |
| Selling, General & Administrative Expenses (SG&A) | 3.2 | 3.5 | 14.6 | 9.1 | 6.6 | 4.1 | 3.7 | 4.4 | 5.1 | 11.1 | 11.3 | 13.8 | 22.1 | 21.5 | 11.9 | 19.2 | 23.6 | 26.7 | 28.2 | 60.5 |
% margin | (5.8) (338.9%) | (16.0) (423.8%) | (46.9) (388.4%) | (34.7) (7,198.9%) | (14.5) (3,047.6%) | (14.5) (777.1%) | (7.6) (170.1%) | (11.5) (252.3%) | (17.4) (487.9%) | (31.3) (844.4%) | (43.7) 0.0% | (41.6) (1,078.7%) | (23.7) (50.7%) | 16.4 21.9% | (54.6) (6,766.4%) | (53.2) (6,185.2%) | (86.2) (4,764.3%) | (72.1) (10,235.6%) | (89.7) 0.0% | 0.3 0.0% |
| Interest Income | 1.9 | 3.2 | 3.1 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 | 4.9 | 0.0 | 0.0 | 0.2 | 1.5 | 10.4 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 1.4 | 2.1 | 0.7 | 0.0 | 0.3 | 0.3 | 4.4 | 16.5 | (8.7) |
| Pre-tax Income | (3.9) | (12.8) | (43.9) | (34.2) | (14.7) | (14.4) | (7.5) | (11.5) | (17.3) | (31.2) | (43.7) | (43.0) | (20.1) | 8.8 | (36.3) | (52.9) | (88.6) | (78.8) | (615.9) | (221.3) |
% effective tax rate | (0.5) 12.8% | (1.8) 13.9% | (3.6) 8.3% | (4.6) 13.3% | (0.9) 6.4% | (3.0) 20.7% | (0.8) 10.1% | (0.9) 7.5% | (1.6) 9.1% | (3.2) 10.2% | (6.6) 15.2% | (7.3) 16.9% | (6.9) 34.5% | (4.3) (49.6%) | (5.8) 15.9% | (0.2) 0.4% | (2.5) 2.8% | (4.4) 5.6% | (0.9) 0.2% | 0.0 0.0% |
% margin | (3.4) (199.7%) | (11.0) (292.1%) | (40.3) (334.1%) | (58.4) (12,109.8%) | (13.7) (2,867.2%) | (11.4) (614.7%) | (6.8) (152.6%) | (10.6) (232.9%) | (15.8) (443.1%) | (28.0) (754.9%) | (37.0) 0.0% | (35.7) (927.6%) | (13.1) (28.1%) | 13.1 17.5% | (30.5) (3,779.1%) | (52.7) (6,127.6%) | (86.1) (4,762.1%) | (74.4) (10,561.1%) | (614.9) 0.0% | (221.3) 0.0% |
| EPS | (0.11) | (0.30) | (0.84) | (1.09) | (0.21) | (0.07) | (0.04) | (0.67) | (3.26) | (0.70) | (0.62) | (0.58) | (0.21) | 0.15 | (0.19) | (0.76) | (0.93) | (0.38) | (0.99) | (0.31) |
| Diluted EPS | (0.11) | (0.30) | (0.84) | (1.09) | (0.21) | (0.07) | (0.04) | (0.67) | (3.26) | (0.70) | (0.62) | (0.58) | (0.20) | 0.15 | (0.19) | (0.76) | (0.93) | (0.38) | (0.99) | (0.31) |
% margin | (5.4) (313.6%) | (11.4) (302.4%) | (37.2) (308.4%) | (29.0) (6,010.3%) | (8.5) (1,790.5%) | (13.3) (716.0%) | (7.1) (159.0%) | (8.7) (191.3%) | (17.3) (486.0%) | (20.0) (537.9%) | (30.9) 0.0% | (41.5) (1,075.8%) | (41.9) (89.5%) | 15.5 20.7% | (21.4) (2,657.4%) | (37.1) (4,317.9%) | (62.7) (3,468.0%) | (52.6) (7,472.8%) | 1.0 0.0% | 0.3 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Summit Therapeutics Inc.'s EBITDA?
As of today, Summit Therapeutics Inc.'s last 12-month EBITDA is ($212.6M), based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Summit Therapeutics Inc.'s EBITDA growth rate?
Over the last year, Summit Therapeutics Inc.'s EBITDA growth was (64.4%). The average annual EBITDA growth rates for Summit Therapeutics Inc. have been 37.7% over the past three years, 42.8% over the past five years.
3) Is Summit Therapeutics Inc.'s EBITDA growth rate Good?
Over the last year, Summit Therapeutics Inc.'s EBITDA growth was (64.4%), which is lower than industry growth of (0.1%). It indicates that Summit Therapeutics Inc.'s EBITDA growth is Bad.